Slide 1: Financial Results Quarter Ended June 30, 2017
Financial Results Quarter Ended June 30, 2017
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : Tuesday, July 18, 2017 Time : 05:00 pm IST Primary Number: +91 22 3938 1071 3940 3977 Available in - Ahmedabad, Bengaluru, Chandigarh, Chennai, Local Access Number: Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers. USA: 1 866 746 2
Slide 4: Q1'FY18 Results Analysis
JUBHANT LIFESCIENCES Q1’FY18 Results Analysis
Slide 5: Income Statement – Q1'FY18
Income Statement – Q1’FY18 Particulars Q1'FY17 Q4'FY17 Q1'FY18 YoY Growth (Rs Crs) (%) Total Revenue from Operations 1,454 1,641 1,596 10% Pharmaceuticals 755 808 818 8% Life Science Ingredients 650 782 737 13% Drug Discovery Solutions 50 51 41 -17% Total Expenditure 1,086 1,336 1,258 16% Other Inco
Slide 6: Financial Highlights – Q1'FY18
Financial Highlights – Q1’FY18 • Consolidated revenue at Rs. 1,596 Crore; up 10% YoY • Pharmaceuticals revenue at record Rs. 818 Crore, contributing 51% to the revenues, up 8% YoY • Life Science Ingredients revenue at Rs. 737 Crore, contributing 46% to the revenues, up 13% YoY • Drug Discovery Solut
Slide 7: Pharmaceuticals Segment Highlights – Q1'FY18
Pharmaceuticals Segment Highlights – Q1’FY18 • Highest-ever Revenues of Rs. 818 Crore, up 8% YoY • Specialty Pharmaceuticals - Injectables revenues of Rs. 469 Crore reported robust growth of 16% YoY and 7% QoQ; contributing 57% to Pharma segment sales and 29% to Company revenue • Generics revenues a
Slide 8: Pharmaceuticals Segment Highlights – Q1'FY18
Pharmaceuticals Segment Highlights – Q1’FY18 Region-wise Revenue (Rs crs) Q1'FY17 Q4'FY17 Q1'FY18 Mix % YoY % QoQ % ROW 8.0% International 705 767 778 95% 10% 1% Europe & India Japan 4.9% North America 514 580 610 75% 19% 5% 12.5% Europe & Japan 106 130 102 12% -4% -21% ROW 85 57 65 8% -24% 14% Nort
Slide 9: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Product pipeline as on June 30, 2017 Dosage (Orals) Injectables Region Total Filings Approval Pending Total Filings Approval Pending US 84 53 31 12 9 3 Canada 22 21 1 13 13 0 Europe 101 94 7 10 10 0 ROW 650 474 176 44 40 4 Total 857 642 215 79 72 7 W
Slide 10: Filings and Approvals
Filings and Approvals Dosage (Orals) Filed 84 ANDAs in the US i. 53 ANDAs have been approved and 31 ANDAs are pending approval ii. Filed 2 ANDAs in FY 18 Made 773 filings in ROW markets including Canada, Europe and Japan i. 589 filings have been approved and 184 filings are pending approval In
Slide 11: Regulatory Status
Regulatory Status Regulatory Cadista Roorkee CMO / Allergy CMO JDI Montreal Nanjangud Agency USA India Spokane Montreal Canada India • All sites successfully inspected and fully compliant with USFDA Mar 2017 Mar 2017 Nov 2016 Dec 2016 Dec 2016 Oct 2015 regulations (USA) • Use the experience from Sep
Slide 12: LSI Segment Highlights – Q1'FY18
LSI Segment Highlights – Q1’FY18 Region-wise Revenue (Rs crs) Q1'FY17 Q4'FY17 Q1'FY18 Mix % YoY % QoQ % ROW International 296 335 312 42% 6% -7% 14.7% Europe, North America and Japan 209 227 204 28% -3% -10% Europe, India North 57.6% ROW 87 108 108 15% 25% 0% America and Japan India 354 447 425 58%
Slide 13: Drug Discovery Solutions Segment Highlights – Q1'FY18
Drug Discovery Solutions Segment Highlights – Q1’FY18 Region-wise Revenue (Rs crs) Q1'FY17 Q4'FY17 Q1'FY18 Mix % YoY % QoQ % ROW International 49 49 41 99% -17% -16% 1.5% Europe & India North America 37 37 30 72% -20% -20% Japan 1.0% 25.2% Europe & Japan 11 11 10 25% -8% -4% North America ROW 1 1 1
Slide 14: Expenditure Analysis – Q1'FY18
Expenditure Analysis – Q1’FY18 Expenses (Rs Crs) Q1'FY17 % of Sales Q1'FY18 % of Sales YoY Growth % Material Cost 464 32% 584 37% 26% Excise Duty on Sales 34 2% 40 2% 16% Power & Fuel Expense 81 6% 90 6% 12% Employee Benefits Expense 296 20% 310 19% 5% Other Expenses 211 14% 234 15% 11% Total Expens
Slide 15: Debt Profile
Debt Profile Particulars 31-Mar-17 30-Jun-17 Foreign Currency Loans ($ Mn) ($ Mn) Standalone 19 19 Subsidiaries 407 387 Total 426 405 Rupee Loans (Rs. Crs) (Rs. Crs) Standalone 1,241 1,161 Subsidiaries 82 127 Total 1,323 1,288 Gross Debt 4,084 3,904 Cash & Equivalent 460 403 Net Debt 3,625 3,501 Cha
Slide 16: Outlook
Outlook We expect continued robust growth going forward, led by momentum in our Specialty Pharmaceuticals - Injectables and Life Science Ingredient business In FY2018, improvement in revenues and profitability is expected • Specialty Pharmaceuticals - Injectables: • Existing business: Growth fro
Slide 17: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1002 Ph: +91-22-6645 1209 E-mail: ravi_agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Kanika Bansal Jubilant Life Sciences Limited Perfect Relati